458-50-4

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-FLUOROANISOLE is used as a key intermediate in the synthesis of orally available mGlu1 receptor enhancers. These enhancers play a crucial role in modulating the activity of metabotropic glutamate 1 (mGlu1) receptors, which are involved in various neurological processes and have potential therapeutic applications in treating conditions such as anxiety, depression, and neurodegenerative diseases.
4-BROMO-3-FLUOROANISOLE's unique chemical structure allows it to interact with mGlu1 receptors, leading to the enhancement of their activity and potentially providing therapeutic benefits in the treatment of the aforementioned conditions. Its use in the pharmaceutical industry is primarily due to its ability to contribute to the development of novel and effective treatments for a range of neurological disorders.

InChI:InChI=1/C7H6BrFO/c1-10-5-2-3-6(8)7(9)4-5/h2-4H,1H3

Upstream product

• 458-52-6 2-fluoro-4-(methoxy)aniline 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 74-88-4 methyl iodide 
• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 
• 121219-03-2 4-bromo-3-fluorophenol 
• 67-56-1 methanol 
• 348-57-2 2,4-difluorobromobenzene 
• 865-33-8 potassium methanolate 
• 77-78-1 dimethyl sulfate 
• 394-42-3 2-fluoro-4-methoxy-benzoic acid 

Downstream Products

• 331-62-4 3-fluoro-4-methoxybenzonitrile 
• 121219-03-2 4-bromo-3-fluorophenol 
• 628692-21-7 2-fluoro-4-methoxyphenyl pinalcolboronate 
• 1160653-94-0 3-bromo-2-fluoro-6-methoxybenzaldehyde 
• 1191045-03-0 1-(2-fluoro-4-methoxy-phenylethynyl)-2,5-dimethoxy-3-methyl-benzene 
• 1022154-92-2 2,2-difluoro-1-(2-fluoro-4-methoxyphenyl)ethanone 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 1351403-10-5 2-fluoro-4-methoxy-1-ethylbenzene 
• 1262414-96-9 2-(2-fluoro-4-methoxyphenyl)isopropane 
• 1351403-45-6 2-fluoro-4-methoxy-1-propylbenzene 
• 1374562-54-5 C₁₅H₂₁FO₃ 
• 1374134-33-4 methyl 3-(2-fluoro-4-methoxyphenyl)-3-hydroxycyclobutanecarboxylate 
• 944317-83-3 methyl 2'-fluoro-4'-methoxy-2-methyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-4-carboxylate 
• 1374132-22-5 methyl 5'-[4-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)2-(3-fluoroazetidin-1-yl)pyrimidin-5-yl]-2'-fluoro-4'-methoxy-2-methylbiphenyl-4-carboxylate 

Relevant academic research and scientific papers

Design of an Electron-Withdrawing Benzonitrile Ligand for Ni-Catalyzed Cross-Coupling Involving Tertiary Nucleophiles

The design of new ligands for cross-coupling is essential for developing new catalytic reactions that access valuable products such as pharmaceuticals. In this report, we exploit the reactivity of nitrile-containing additives in Ni catalysis to design a benzonitrile-containing ligand for cross-coupling involving tertiary nucleophiles. Kinetic and Hammett studies are used to elucidate the role of the optimized ligand, which demonstrate that the benzonitrile moiety acts as an electron-acceptor to promote reductive elimination over β-hydride elimination and stabilize low-valent Ni. With these conditions, a protocol for decyanation-metalation and Ni-catalyzed arylation is conducted, enabling access to quaternary α-arylnitriles from disubstituted malononitriles.

Transition-metal-free decarboxylative bromination of aromatic carboxylic acids

Methods for the conversion of aliphatic acids to alkyl halides have progressed significantly over the past century, however, the analogous decarboxylative bromination of aromatic acids has remained a longstanding challenge. The development of efficient methods for the synthesis of aryl bromides is of great importance as they are versatile reagents in synthesis and are present in many functional molecules. Herein we report a transition metal-free decarboxylative bromination of aromatic acids. The reaction is applicable to many electron-rich aromatic and heteroaromatic acids which have previously proved poor substrates for Hunsdiecker-type reactions. In addition, our preliminary mechanistic study suggests that radical intermediates are not involved in this reaction, which is in contrast to classical Hunsdiecker-type reactivity. Overall, the process demonstrates a useful method for producing valuable reagents from inexpensive and abundant starting materials.

Fast and Tight Boronate Formation for Click Bioorthogonal Conjugation

A new click bioorthogonal reaction system was devised to enable the fast ligation (kON≈340 m-1 s-1) of conjugatable derivatives of a rigid cyclic diol (nopoldiol) and a carefully optimized boronic acid partner, 2-methyl-5-carboxymethylphenylboronic acid. Using NMR and fluorescence spectroscopy studies, the corresponding boronates were found to form reversibly within minutes at low micromolar concentration in water, providing submicromolar equilibrium constant (Keq≈105-106 m-1). Efficient protein conjugation under physiological conditions was demonstrated with model proteins thioredoxin and albumin, and characterized by mass spectrometry and gel electrophoresis.

Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

Substituted inmidazoles as bombesin receptor subtype-3 modulators

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Synthesis of novel structurally simplified estrogen analogues with electron-donating groups in ring A

A library of 25 novel estrogen analogues were prepared in five to eight steps from mostly commercially available substituted anisoles via bromination, formylation, Corey-Fuchs reaction, elimination, and Sonogashira reaction. Georg Thieme Verlag Stuttgart.

Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols

In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzen

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.